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Objective: Interleukin (IL)-18 is a pleotropic cytokine involved in various inﬂammatory disorders. The
transcription factor, nuclear factor kappa-B (NF-kB), is thought to play an important role in IL-18
signaling. The present study proposes a novel role for IL-18 in cholesterol efﬂux and plaque stability and
demonstrates that pyrrolidine dithiocarbamate (PDTC), a NF-kB inhibitor blocks IL-18 signaling in
apolipoprotein (Apo) E/ mice.
Methods: Three groups of normal chow-diet-fed, male Apo E/ mice, aged 12 weeks (n = 6/group) were
employed: Gp I, PBS (2 mo); Gp II, recombinant (r)IL-18 (1 mo) followed by PBS (1 mo); Gp III, rIL-18
(1 mo) followed by PDTC (1 mo).
Results: Signiﬁcantly augmented expression of IL-18 receptor (R)a by ﬂuorescence-activated cell sorting
analysis and plasma IL-18 was observed in Gp II. There was a signiﬁcant increase in total cholesterol and low-
density lipoprotein cholesterol whereas high-density lipoprotein cholesterol was signiﬁcantly decreased in
Gp II. However, this pattern was reversed in Gp III. Signiﬁcantly augmented mRNA expression of IL-18, CD36,
matrix metalloproteinase (MMP)-9, and NF-kB was observed in Gp II but liver X receptor alpha (LXR-a) gene
was signiﬁcantly reduced. A signiﬁcant increase in frequency of atherosclerotic lesions was observed in Gp II
animals, whereas there was a signiﬁcant decrease in the Gp III.
Conclusion: IL-18 administration initiates inﬂammatory cascade by binding with IL-18 Ra via NF-kB
which is involved in progression and destabilization of atherosclerotic plaques in Apo E/ mice. This
study also reveals that NF-kB blockade with PDTC, blocks IL-18 signaling through down-regulation of IL-
18, IL-18 Ra, CD36, and MMP-9, thus reducing inﬂammation and restoring plaque instability via
upregulation of LXR-a.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Endothelial dysfunction, imbalanced lipid metabolism, and a
maladaptive inﬂammatory immune response are hallmarks of
atherosclerotic disease. The nuclear receptors, i.e. liver X receptor
alpha (LXR-a) and peroxisome proliferator-activated receptors
(PPARs) are not only involved in cholesterol efﬂux via macrophages
[1], but also regulate the expression of many genes involved in the* Corresponding author at: Department of Experimental Medicine and Biotech-
nology, Research Block-B, Postgraduate Institute of Medical Education and Research
(PGIMER), Chandigarh 160012, India. Tel.: +91 172 2747585x5235;
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsproduction of proinﬂammatory cytokines, adhesion molecules,
and scavenger receptors (CD36, SR-A, SR-B1) that control the
native and oxidized low-density lipoprotein (ox-LDL) uptake, an
important step in foam cell formation [2]. These oxidized lipids
activate nuclear factor-kB (NF-kB) which transcriptionally reg-
ulates many cellular genes implicated in early immune, acute-
phase, and inﬂammatory responses [3]. Acute or chronic activation
of NF-kB, is also shown to activate matrix metalloproteinase-9
(MMP-9) resulting in atherosclerotic plaque instability and
rupture [4]. Therefore, inhibition of NF-kB is functionally impor-
tant and suggests therapies for diseases related to the acute or
chronic activation of NF-kB.
The apolipoprotein E knockout (Apo E/ mice) mouse fed on a
standard chow diet, spontaneously develops atherosclerotic reserved.
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a distribution similar to human atherosclerosis and can be
accelerated by feeding a Western diet [5,6]. Therefore Apo E/
mice were chosen as an animal model in our study.
Interleukin-18 (IL-18) is a proinﬂammatory cytokine with
pleotropic properties [5] and induced IL-18 expression has been
observed in unstable human atherosclerotic plaques from asymp-
tomatic patients [7]. An over expression of murine IL-18 binding
protein, the endogenous inhibitor of IL-18 is shown to reduce
atherosclerotic lesion development in Apo E/ mice [8]. IL-18
acts by binding to its receptor (IL-18 Ra), is expressed on a variety
of cells, and initiates signaling [9].
In view of the above, we hypothesized that exogenous IL-18
treatment may aggravate atherosclerosis by modulating expres-
sion of crucial genes and that, PDTC a speciﬁc NF-kB inhibitor may
inhibit IL-18-induced signaling and thereby halt atherosclerotic
progression. Here, we report a novel pathway of IL-18-induced
atherosclerosis involving CD36 and NF-kB crosstalk and demon-
strate that pyrrolidine dithiocarbamate (PDTC) successfully
inhibits IL-18-induced atherosclerosis.
Materials and methods
Lyophilized recombinant mouse IL-18 (rIL-18) was purchased
from R&D Systems, Inc, Minneapolis, MN, USA (Catalog#: B002-5)
and reconstituted as per manufacturer’s protocol. PDTC (Catalog no
P8765) was purchased from Sigma Aldrich, St. Louis, MO, USA.
IL-18 treatment
Eighteen male Apo E/ mice (12 weeks old), with the C57BL/6
strain background, were obtained from the Centre for Cellular and
Molecular Biology (CCMB), Hyderabad, India. The animal protocol
was approved by the Institute Animal Ethics Committee (IAEC)
(reference No. 49/IAEC/237) of PGIMER, Chandigarh. All the animal
procedures were performed following the US National Institutes of
Health protocol. Polymerase chain reaction (PCR) was used to
identify mice homozygous for Apo E/ [10]. After acclimatiza-
tion, mice were divided into three groups of 6. Group I received
daily intraperitoneal injections of phosphate buffered saline (PBS)
(containing 0.1% bovine serum albumin and 1% sucrose), while
Group II received daily intraperitoneal injections of rIL-18 (30 ng/g
body weight) for one month followed by PBS for one month
[11]. Group III received daily intraperitoneal injections of rIL-18
(30 ng/g body weight) for one month followed by PDTC for one
month (10 mg/kg body weight) [12].
Processing of tissues
At the end of the experimental period, mice were euthanized by
intraperitoneal injection of ketamine plus xylazine (90 + 10 mg/kg
body weight) [11]. Terminal blood samples were collected by
puncture of the right ventricle, and mice were perfused with PBS.
Hearts were separated from the aorta at the base, embedded in
optimum cutting temperature (OCT, cryo embedding media) and
frozen at 80 8C. Aortic tissue was removed from the ascending
aorta to the level of diaphragm, embedded in OCT and frozen at
80 8C for immunohistochemical analysis. Hearts were trans-
versely cut into two parts. The half containing the apex was stored
at 80 8C for molecular biology work. The other half comprising
the base and origin of the aorta was embedded in OCT and multiple
frozen sections were cut. The leftover frozen tissue remnant was
then brought to room temperature and ﬁxed in 10% buffered
formalin for histopathological evaluation and Masson’s trichrome
staining [11].Quantiﬁcation of atherosclerotic lesions
Assessment and quantiﬁcation of atherosclerotic lesions was
carried out by two independent pathologists in a blinded manner.
Size of the atherosclerotic lesions was determined in sections from
ascending aorta (four), cut 8-mm thick, collected at 80-mm
intervals, starting at the region where aortic sinus becomes the
ascending aorta and lesion areas, deﬁned by Oil Red O (ORO)
staining of the intima, were determined using Image-Pro software
(Image J; Media Cybernetics Inc, Rockville, MD, USA). Mean lesion
area derived from the 4 serial sections was taken as the mean
lesion size for each animal [13].
Immunohistochemistry
Brieﬂy, frozen tissue sections (8 mm) of tissues were ﬁxed with
acetone for 20 min, followed by endogenous peroxidase blocking
with 0.3% H2O2 solution in methanol. Sections were incubated with
2.5% horse serum followed by incubation with respective primary
antibodies, overnight at 4 8C. Sections were subsequently incubat-
ed with biotinylated secondary antibodies and a streptavidin-
peroxidase complex (PK-7800, Vector Laboratories, Burlingame,
CA, USA), developed with diamino benzidine (DAB) substrate
(0.05% DAB–0.015% H2O2 in PBS; Cat No. D 5637, Sigma Aldrich)
and counterstained with hematoxylin. Slides were dehydrated and
mounted with DPX. For immunostaining: anti-mouse liver X
receptor-a (LXR-a) goat polyclonal antibody (sc-1201, 1:50
dilution; Santa Cruz Biotechnology, Dallas, TX, USA), anti-mouse
CD36 rabbit polyclonal antibody (ab78054, 2.5 mg/ml; Abcam,
Cambridge, MA, USA), anti-mouse nuclear factor-kB (NF-kB p65
antibody, RelA) rabbit polyclonal antibody [PC137, 1:100 dilution;
Calbiochem (EMD Millipore, Billerica, MA, USA)] and anti-mouse
MMP-9 goat polyclonal antibody (sc-6840, 1:50 dilution; Santa
Cruz Biotechnology) were used respectively.
Serum cholesterol and lipoprotein proﬁle
At the end of the study, serum total cholesterol (TC; Cat No.
11506), triglycerides (TG; Cat No. 11528), and high-density
lipoprotein cholesterol (HDL-C; Cat No. 11648) levels were
determined using commercially available enzymatic kits (Biosys-
tems Kit, Barcelona, Spain). Low-density lipoprotein cholesterol
(LDL-C) and very low-density lipoprotein-cholesterol (VLDL-C)
concentrations were calculated using Friedwald’s formula [14].
Friedwald’s formula:
LDL-C ¼ TC  HDL-C þ TG
5
 
VLDL-C ¼ TG
5
Therefore, LDL-C = TC  (HDL-C + VLDL-C). Hence, VLDL-C = TC 
(HDL-C + LDL-C). So above equation is veriﬁed and is correct.
Fluorescence-activated cell sorting analysis of IL-18 Ra
IL-18 Ra expression was analyzed in the blood using
allophycocyanin (APC)-conjugated rat monoclonal anti-mouse
IL-18 Ra antibody (R&D, Minneapolis, MN, USA; Cat. No:
FAB1216A, Lot No: ABKA02, 10 mg/ml). Tubes were incubated
with ﬂuorescence-activated cell sorting (FACS) lysis buffer for
10 min at RT and cells were washed twice in ﬂow cytometry
staining buffer. IL-18 Ra expression was analyzed using Becton
Dickinson FACS Aria II ﬂow cytometer using DIVA software (Becton
Dickinson, Franklin Lakes, NJ, USA).
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Due to limited availability of the tissues, the mRNA levels of
LXR-a, CD36, NF-kB, and IL-18 were determined in the heart and
MMP-9 was determined in the aorta by RT-PCR. The following
mouse speciﬁc primers were used: LXR-a: F-50-CCTTCCTCAAG-
GACTTCAGTTACAA-30, R-50-CATGGCTCTGGAGAACTCAAAGAT-30;
CD36: F-50-ACATTTGCAGGTCTATCTACG-30, R-50-AATGGTTGTCTG-
GATTCTGG-30; MMP-9: F-50-CATTCGCGTGGATAAGGAGT-30, R-50-
CACTGCAGGAGGTCGTAGG-30; IL-18: F-50-ACGTGTTCCAGGACA-
CAACA-30, R-50-ACAAACCCTCCCCACCTAAC-30; NF-kB: F-50-TGGG
GGCCTTGCTTGGCAAC-30, R-50-GAGGTCCCCAGGGGTGTGGG-30;
and b-Actin: F-50-GCATTGCTGACAGGATGCAG-30, R-50-CCTGCT
TGCTGATCCACATC-30. Expression as fold increase/decrease was
calculated using the 2DDCT method [15]. The data were expressed
as relative mRNA expression normalized to mouse b-actin mRNA
expression.
IL-18 enzyme-linked immunosorbent assay
IL-18 was determined in the plasma samples with commer-
cially available mouse speciﬁc IL-18 enzyme-linked immunosor-
bent assay kit (7625; MBL, Nagoya, Japan). The sensitivity of the kit
was 25 pg/ml. Results are expressed in units as pg/ml.
Statistical methods
All data are expressed as mean  SD. Data analyses were
performed using Graph Pad Prism 5.00.288 software (La Jolla, CA,Fig. 1. Plasma IL-18 levels, IL-18 mRNA, and IL-18 Ra expression in Apo E/ mice. (A)
expression of IL-18. (C) Histogram represents the ﬂuorescence intensity of IL-18 Ra anti
(APC)-conjugated rat monoclonal anti-mouse IL-18 Ra], Gp I (phosphate-buffered saline 
buffered saline for 1 month), and Gp III (recombinant IL-18 for 1 month followed by PDT
receptor; Apo, apolipoprotein; PDTC, pyrrolidine dithiocarbamate.USA). Statistical analysis between the groups was done by unpaired
Student’s ‘t’ test and ANOVA after testing that the data complied with
the constraints of parametric analysis. Where parametric analysis
was not permissible, analysis between groups was conducted using
the Tukey test. Values with p  0.05 were considered statistically
signiﬁcant.
Results
IL-18 levels and IL-18 Ra expression in IL-18-treated Apo E/ mice
Plasma IL-18 levels were found to be signiﬁcantly increased in
Group II animals vs. Group I (170  9.16 pg/ml vs.
1178.66  8.08 pg/ml, p < 0.001), whereas these levels were signiﬁ-
cantly decreased in Group III vs. II animals (1178.66  8.08 pg/ml vs.
883.33  76.37 pg/ml, p < 0.001) (Fig. 1A). IL-18 mRNA expression in
the heart of Apo E/ mice was also augmented by 6-fold in Group II
mice as compared to the Group I animals (p < 0.001, Fig. 1B) and was
found to be signiﬁcantly reduced in Group III mice (p < 0.001, Fig. 1B).
FACS analysis revealed that in Group II IL-18 Ra expression was
signiﬁcantly enhanced on peripheral blood mononuclear cells
(15.2  1.3 vs. 59.7  3.05), whereas it was downregulated in Group
III (59.7  3.05 vs. 12.76  2.83) (p < 0.001, Fig. 1C and D).
Lipids and lipoproteins in IL-18-treated Apo E/ mice
When compared with Group I, there was non-signiﬁcant
change in the body weight of Group II and Group III mice Representative bar diagram showing circulatory levels of IL-18 (pg/ml). (B) mRNA
body. (D) Bar graph represents % expression of IL-18 Ra. IL-18 Ra [allophycocyanin
injected for 2 months), Gp II (recombinant IL-18 for 1 month followed by phosphate-
C for 1 month) (n = 6) (***p < 0.001 vs. Gp I, ###p < 0.001 vs. Gp II). IL, interleukin; R,
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signiﬁcant increase in serum TC and LDL-C and a signiﬁcant decrease
in HDL-C levels were observed in Group II mice vs. Group I (Fig. 2A).
However, a signiﬁcant decrease in serum TC and LDL-C, and a
signiﬁcant increase in HDL-C levels was observed in Group III mice vs.
Group II (Fig. 2A). The change in TG and VLDL-C levels was statistically
non-signiﬁcant.
Expression of CD36 and MMP-9 in IL-18-treated Apo E/ mice
We observed signiﬁcantly augmented, i.e. 8-fold and 3-fold
mRNA expression of the CD36 and MMP-9 in heart and aortic
tissues of Group II mice (p < 0.001; Figs. 2B and 3A), whereas these
were signiﬁcantly downregulated 7-fold and 2.8-fold in Group
III animals. We also examined protein expression of CD36 in heart
(Fig. 2C) and MMP-9 expression in aorta by immunohistochemis-
try (Fig. 3B). An increased CD36 expression was observed in
cardiomyocytes and microvascular endothelial cells, whereas
MMP-9 expression was increased in the endothelial cell lining
in Group II mice vs. Group I, and a reduced expression was noted in
Group III animals.
Transcriptional/translation expression of LXR-a in IL-18-treated Apo
E/ mice
We examined LXR-a mRNA expression in pooled heart tissues.
LXR-a mRNA expression was found to be signiﬁcantly attenuated
in Group II mice vs. Group I (p < 0.001). However, LXR-a
expression was signiﬁcantly increased in Group III animals
(Fig. 3A). Similar results were observed by immunohistochemistry
analysis where Group II mice had reduced LXR-a proteinFig. 2. Lipid and lipoprotein proﬁle and scavenger receptor CD36 expression in apolipopr
(mg/dl). (B) mRNA expression of CD36. (C) Sections from heart showing CD36 immunost
in cardiomyocytes and microvascular endothelial cells by red arrow. Original magniﬁ
(recombinant IL-18 for 1 month followed by phosphate-buffered saline for 1 month), G
#p < 0.05 vs. Gp II; ***p < 0.001 vs. Gp I, ###p < 0.001 vs. Gp II). TC, total cholesterol; 
lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; IL, interleuki
referred to the web version of this article.)expression in cardiomyocytes as compared to Group I, and its
expression was augmented in Group III mice (Fig. 3B).
Transcriptional/translation expression of NF-kB p65 RelA in IL-18-
treated Apo E/ mice
A signiﬁcantly augmented mRNA expression of NF-kB was
observed in heart tissues of Group II mice, i.e. 7-fold vs. Group I
(p < 0.001; Fig. 3A) and it was signiﬁcantly downregulated in
Group III animals. Further, we also examined expression of NF-kB
p65 protein in heart sections by immunohistochemistry. An
augmented NF-kB p65 expression was observed in cardiomyocytes
of Group II animals as compared to the Group I and Group III
animals (Fig. 3B).
Histological examination, Masson’s trichrome and ORO staining
Based on hematoxylin and eosin stains, we observed increased
percentage of atheromatous lesions in aorta of Group II vs. Group
I and Group III mice. No remarkable changes were observed in any
of the groups in heart and coronary arteries (Fig. 4A–C). MT
staining demonstrated different grades of atherosclerotic lesions
in aorta. Increased number of foam cells, inﬂammatory cells,
smooth muscle cells and collagen were present in the lesions of
Group II mice (Fig. 5A). Based on ORO staining, a signiﬁcant
increase in percentage lesion area in the ascending aorta and
aortic arch was observed in Group II mice vs. Group I
(24.09  13.32% vs. 1.52  0.57%; p < 0.001) whereas a signiﬁcant
decrease was observed in PDTC-treated Group III animals
(24.09  13.32% vs. 3.37  0.99%; p < 0.001; Gp II vs. Gp III;
Fig. 5B and C).otein E/ mice. (A) Representative bar diagram shows lipid and lipoprotein proﬁle
aining rabbit polyclonal anti-mouse. CD36 is indicated by black arrow (brown stain)
cations, C, 400. Gp I (phosphate-buffered saline injected for 2 months), Gp II
p III (rIL-18 for 1 month followed by PDTC for 1 month) (n = 6) (*p < 0.05 vs. Gp I;
HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; LDL-C, low-density
n. (For interpretation of the references to color in this ﬁgure legend, the reader is
Fig. 3. mRNA expression and immunohistochemical analysis of MMP-9, LXR-a, and NF-kB p65 in apolipoprotein E/ mice. (A) mRNA expression of MMP-9, LXR-a and NF-
kB p65. (B) Representative sections from heart and aorta [atherosclerotic plaques (red arrow)]. MMP-9 immunostaining goat polyclonal anti-mouse MMP-9 in aorta is
indicated by black arrow (brown stain) in endothelial cell lining, LXR-a immunostaining goat polyclonal anti-mouse LXR-a in heart sections is indicated by black arrow
(brown stain) in cardiomyocytes, and NF-kB p65 immunostaining rabbit polyclonal anti-mouse NF-kB p65 in heart sections is indicated by black arrow (brown stain) in
cardiomyocytes. Gp I (phosphate-buffered saline injected for 2 months), Gp II (recombinant IL-18 for 1 month followed by phosphate-buffered saline for 1 month), Gp III
(recombinant IL-18 for 1 month followed by PDTC for 1 month) (n = 6). Original magniﬁcations, 200 (*p < 0.05 vs. Gp I; ***p < 0.001 vs. Gp I, ###p < 0.001 vs. Gp II). MMP-9,
matrix metalloproteinase-9; LXR-a, Liver X receptor alpha; NF-kB, nuclear factor kappa-B; IL, interleukin; PDTC, pyrrolidine dithiocarbamate. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Our results clearly indicate a crucial role of pro-inﬂammatory
cytokine IL-18 in atherosclerotic plaque development, progression,
and stability. Only two studies reported in mice models have
reported that IL-18 administration promotes development of
atherosclerosis [11,16]. Mallat et al. demonstrated increased IL-18
expression in human carotid atherosclerotic plaques [7]. In the
current study, administration of rIL-18 in Apo E/ mice initiated
an inﬂammatory response that was associated with upregulation
of cell adhesion molecules like ICAM-1 and VCAM-1 (data not
shown) resulting in endothelial dysfunction. Endothelial dysfunc-
tion and presence of increased oxidative stress may give rise to
increased Ox-LDL levels. Although we did not determine Ox-LDL
levels, a signiﬁcantly increased scavenger receptor (CD36)
expression with IL-18 administration in our study could be due
to raised Ox-LDL that may lead to foam cell formation and thus
development and progression of atherosclerosis. CD36 mRNA
expression has been shown to be upregulated in macrophages by
inﬂammatory cytokines, and blocking CD36 expression or its
downstream signaling is shown to inhibit Ox-LDL uptake and limit
experimental atherosclerosis in mice [17,18]. Another mechanism
of lipid-independent atherosclerotic plaque development due to
IL-18 could be due to increased MMP-9 expression in the present
study. IL-18 has been shown to induce MMPs in murine peritonealmacrophages and human monocytes [19,20]. Our data demon-
strated that atherosclerotic plaques were rich in inﬂammatory
cells, smooth muscle cells, and collagen, thus induction of MMP-9
via IL-18 may be a crucial link in the chain of events promoting
plaque rupture, thrombosis, and myocardial infarction. Further,
interferon (IFN)-g and IL-6 induction by IL-18 could be another
mechanism by which IL-18 may increase atherosclerosis indepen-
dent of cholesterol levels. In this context, in IL18 /  Apo E/
mice, reduced lesion size and lesion composition was observed
which was found to be independent of cholesterol and triglycer-
ides and lack of IFN-g release [21].
Signiﬁcantly augmented plasma IL-18 levels and IL-18 mRNA
expression in our study also support the above statement.
Increased serum IL-18 levels were found to be positively correlated
with carotid intima media thickness (IMT) and coronary athero-
sclerosis in type II diabetics and myocardial infarction patients,
respectively [22,23]. Our data are in tune with these reports and
are also strengthened by ﬁnding increased IL-18 Ra expression on
PBMCs with rIL-18 treatment in our study.
A signiﬁcant downregulation of IL-18-induced molecules such
as IL-18, IL-18 Ra, CD36, MMP-9, NF-kB, and upregulation of LXR-
a was observed with PDTC demonstrating that IL-18 acts through
NF-kB pathway. PDTC is well tolerated below 50 mg/kg in vivo
[12]. In RA synovial ﬁbroblasts, PDTC has been shown to inhibit IL-
18-induced NF-kB activation and IL-18 has been shown to activate
Fig. 4. Hematoxylin and eosin (H&E) staining of heart, aorta, and coronary artery (CA) of apoliprotein E/ mice. Representative sections from heart, aorta, and CA showing
atherosclerotic plaques (arrow) and CA (H&E stain). Gp I (phosphate-buffered saline injected for 2 months), Gp II (recombinant interleukin-18 for 1 month followed by
phosphate-buffered saline for 1 month), and Gp III (recombinant interleukin-18 for 1 month followed by pyrrolidine dithiocarbamate for 1 month) (n = 6). Original
magniﬁcations, A 100, B 200 and C 400.
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[24,25]. IL-18 binding to IL-18 Ra results in upregulation of IL-1R-
associated kinase (IRAK) and tumor necrosis factor (TNF) receptor-
associated factor 6 (TRAF-6) resulting in nuclear translocation of
NF-kB in mouse cell lines [26]. Bond et al. [27] reported that NF-kB
activity was required for upregulation and production of MMP-9 in
rabbit and human VSMCs. Both MMP-2 and MMP-9 were found to
be signiﬁcantly decreased with PDTC treatment in spontaneously
hypertensive rats [28]. These studies support our ﬁndings that
inhibition of NF-kB downregulates IL-18-induced proinﬂamma-
tory genes.
Various studies using LXR knockouts and LXR agonists suggest
that LXR-a is not only an important regulator of cholesterol efﬂux
in macrophages [29]. It is also anti-inﬂammatory and antagonizes
the process of Ox-LDL uptake and foam cell formation, thus
preventing atherosclerotic lesion formation. Our observation that
IL-18 attenuates LXR-a in a NF-kB dependent manner is the ﬁrst
report in the literature.
Our ﬁndings demonstrate that IL-18 administration increased
serum cholesterol and lipoprotein-cholesterol distribution in mice.
Contrary to our reports, few studies did not demonstrate any
effects of IL-18 on cholesterol levels [11,16]. Apo E/ mice are
known to accumulate cholesterol-rich remnant particles with
plasma cholesterol levels reaching 400 mg/dl, even when fed a
regular low-fat, low-cholesterol diet. Also, humans lacking apo E
(extremely rare) are reported to have elevated remnant cholesterol
in plasma [30].
Chronic systemic inﬂammation through IL-18 may give rise to
dysfunctional or proinﬂammatory HDL and therefore may cause
dysregulated reverse cholesterol transport, thus resulting in
increased cholesterol levels due to IL-18. Cholesterol levels can
increase due to isoprenoid generation by endogenous cellularcholesterol synthesis as well as by cholesterol synthesis in
activated monocytes during the inﬂammatory response. Isopre-
noids are an integral component of the signaling pathway for IL-6-
mediated inﬂammation and there is plenty of evidence in the
literature demonstrating that IL-18 induces IL-6 production both in
vitro and in vivo [31,32]. Increased IL-6 production may give rise to
increased C-reactive protein (CRP) levels which could also be a
trigger for increased cholesterol levels as statin-like drugs are
shown to lower LDL-C and non-HDL-C and thus also lower levels of
CRP.
Our data demonstrated signiﬁcant atherosclerotic lesion
development post-IL-18 treatment, highlighting its role as a
proatherogenic cytokine. Also, a robust hypolipidemic effect of
PDTC was observed in our study as compared to the controls. PDTC
has been shown to attenuate plasma TG and VLDL-C and restore
HDL-C levels in obese db/db mice via reduction in TNF-a and IL-6
levels [33].
Although a partial inhibition of IL-18 levels was observed in
Group III mice, it almost abolished the atherosclerotic lesions in
this group. These ﬁndings may be explained on the basis of the
involvement of upstream and downstream players in IL-18
signaling leading to atherosclerotic changes. Signiﬁcant neutrali-
zation of IL-18-induced signaling by PDTC as observed via blockage
of IL-18 as well as NF-kB activation could be responsible for the
observed effect. Our ﬁndings are further strengthened by a report
which observed that inhibiting NF-kB activity reduces atheroscle-
rosis in Apo E/LDLR double knockout (KO) mice [34].
To the best of our knowledge, our study is the ﬁrst report in the
literature that demonstrates that exogenous rIL-18 administration
signiﬁcantly upregulates CD36 and MMP-9 expression via NF-kB
pathway, thus suggesting a crosstalk involved in the progression
and destabilization of atherosclerotic plaques. Downregulation of
Fig. 5. Characterization and quantiﬁcation of atherosclerotic lesions in apolipoprotein E/mice. (A) Masson’s trichrome staining in sections of aorta. Collagen deposition
(blue; arrow) and muscle ﬁbers (red). (B) Oil Red O staining in sections of aorta showing lipid deposition (atherosclerotic plaques) (arrow). (C) Bar graph represents
quantitative computer-assisted image analysis of lipid deposition. Gp I (phosphate-buffered saline injected for 2 months), Gp II (recombinant IL-18 for 1 month followed by
phosphate-buffered saline for 1 month), and Gp III (rIL-18 for 1 month followed by PDTC for 1 month) (n = 6). Original magniﬁcations, A 100 and B 200 (***p < 0.001 vs. Gp I,
###p < 0.001 vs. Gp II). IL, interleukin; PDTC, pyrrolidine dithiocarbamate. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
O.M. Bhat et al. / Journal of Cardiology 66 (2015) 28–3534LXR-a by IL-18 and its upregulation by PDTC is another signiﬁcant
observation in our study. Our data also shows that PDTC protects
against IL-18-induced atherosclerosis via NF-kB inhibition.
Concluding, our study highlights IL-18 and NF-kB as important
therapeutic targets for prevention of atherosclerotic plaque
development and to limit plaque complications. These ﬁndings
open up a new vista for future research in human subjects to
explore the molecular targets of IL-18 and NF-kB-mediated
signaling.
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